Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Diabetic Neuropathy Market Size Changed, over the years?

In recent years, the size of the diabetic neuropathy market has experienced substantial growth. It is projected to expand from $5.79 billion in 2024 to $6.27 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the historical period include a rise in global instances of diabetes, improved awareness and diagnostic measures, advances in diabetic care, increased healthcare spending, investment in research and development, and initiatives aimed at educating patients.

How Much Will the Diabetic Neuropathy Market Be Worth in 2029?

Anticipated to undergo swift expansion in the coming years, the market for diabetic neuropathy is projected to reach a value of $9.3 billion by 2029, culminating in a compound annual growth rate (CAGR) of 10.4%. Several factors contributing to this growth during the projection period include progress in neuroimaging, growth in clinical trials, the consistent increase in diabetes patients, advancement in precision medicine approaches, the expansion of regenerative medicine, and the promotion of patient advocacy and support programs. Key trends during this projection period incorporate joint ventures in medical research, the rise of digital healthcare solutions, technological advancements in the field of diagnosis, neuroprotective treatments, customized therapeutic strategies, and the integration of artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp

Which is the Largest Company in the Diabetic Neuropathy Market?

Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.

What Are the Main Market Drivers in the Diabetic Neuropathy Industry?

The steady increase in diabetes cases worldwide is projected to fuel the expansion of the diabetic neuropathy market. The inability of the body to properly utilize and store glucose, a kind of sugar, results in diabetes, a chronic disorder. This happens either when there is insufficient production of insulin, a hormone that controls blood sugar, or when the body ineffectively uses insulin. Diabetic neuropathy, a nerve damage condition, can affect diabetes patients, with diverse types of nerve injuries leading to various symptoms. As per the IDF Diabetes Atlas report published by the International Diabetes Federation in August 2022, a Belgium-based global diabetic community spearheading more than 230 national diabetes associations, diabetes was the cause of 6.7 million deaths in 2021, translating to one fatality every five seconds. Presently, there are 537 million adults (between 20-79 years) or one in ten individuals worldwide living with diabetes. It’s projected that this figure will surge to 643 million by 2030 and further to 783 million by 2045. Consequently, the increasing incidence of diabetes is propelling the growth of the diabetic neuropathy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9057&type=smp

How Is the Diabetic Neuropathy Market Segments Structured?

The diabetic neuropathy market covered in this report is segmented –

1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy

2) By Drug Class: Analgesics, Anti-Depressants, Anti-Convulsants, Other Drug Classes

3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments

4) By Distribution Channel: Online Distribution, Offline Distribution

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyneuropathy

2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy, Gastrointestinal Autonomic Neuropathy, Genitourinary Autonomic Neuropathy

3) By Proximal Neuropathy: Diabetic Amyotrophy, Lumbosacral Plexus Neuropathy

4) By Focal Neuropathy: Cranial Neuropathy, Cervical Radiculopathy, Other Focal Neuropathies

What Strategic Trends Are Transforming the Diabetic Neuropathy Market?

In the diabetic neuropathy market, leading companies are focusing on creating advanced products such as the neuromodulation therapy device, aimed at improving treatment alternatives for individuals affected by the chronic pain that comes with diabetic neuropathy. These devices offer non-invasive methods of treating the condition by altering nerve activity to alleviate pain, enhance nerve function and aid in healing the damage caused by diabetics. For example, in January 2024, Neuralace Medical, Inc., a company based in the US that offers non-drug pain management treatments, received FDA approval for Axon Therapy for Chronic Painful Diabetic Neuropathy. The Axon Therapy device is specifically crafted to address chronic painful diabetic neuropathy (CPDN). This cutting-edge therapy adopts neuromodulation methods to aid in pain relief for diabetic neuropathy patients, representing a significant improvement in pain management solutions for those battling this ailment. This approval underlines the device’s safety and effectiveness, paving the way for Neuralace to kick-start commercialization and broaden the availability of efficient treatment options for CPDN patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Which Global Regions Offer the Highest Growth in the Diabetic Neuropathy Market?

North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9057

This Report Delivers Insight On:

1. How big is the diabetic neuropathy market, and how is it changing globally?

2. Who are the major companies in the diabetic neuropathy market, and how are they performing?

3. What are the key opportunities and risks in the diabetic neuropathy market right now?

4. Which products or customer segments are growing the most in the diabetic neuropathy market?

5. What factors are helping or slowing down the growth of the diabetic neuropathy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model